PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Нема приказа
Аутори
Banach, MaciejRizzo, Manfredi
Obradović, Milan M.
Montalto, Giuseppe
Rysz, Jacek
Mikhailidis, Dimitri P.
Isenović, Esma R.
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins. We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved.
Кључне речи:
Cardiovascular diseases / hyperlipidemia / low-density lipoprotein / low-density lipoprotein receptor / proprotein convertase subtilisin/kexin 9 / statinsИзвор:
Current Pharmaceutical Design, 2013, 19, 21, 3869-3877Финансирање / пројекти:
- Хормонска регулација експресије и активности азот оксид синтазе и натријум-калијумове пумпе у експерименталним моделима инсулинске резистенције, дијабетеса и кардиоваскуларних поремећаја (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/13816128113199990303
ISSN: 1381-6128; 1873-4286
PubMed: 23286435
WoS: 000318687100011
Scopus: 2-s2.0-84871975694
Колекције
Институција/група
VinčaTY - JOUR AU - Banach, Maciej AU - Rizzo, Manfredi AU - Obradović, Milan M. AU - Montalto, Giuseppe AU - Rysz, Jacek AU - Mikhailidis, Dimitri P. AU - Isenović, Esma R. PY - 2013 UR - https://vinar.vin.bg.ac.rs/handle/123456789/5502 AB - Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins. We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved. T2 - Current Pharmaceutical Design T1 - PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders? VL - 19 IS - 21 SP - 3869 EP - 3877 DO - 10.2174/13816128113199990303 ER -
@article{ author = "Banach, Maciej and Rizzo, Manfredi and Obradović, Milan M. and Montalto, Giuseppe and Rysz, Jacek and Mikhailidis, Dimitri P. and Isenović, Esma R.", year = "2013", abstract = "Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins. We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved.", journal = "Current Pharmaceutical Design", title = "PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?", volume = "19", number = "21", pages = "3869-3877", doi = "10.2174/13816128113199990303" }
Banach, M., Rizzo, M., Obradović, M. M., Montalto, G., Rysz, J., Mikhailidis, D. P.,& Isenović, E. R.. (2013). PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. in Current Pharmaceutical Design, 19(21), 3869-3877. https://doi.org/10.2174/13816128113199990303
Banach M, Rizzo M, Obradović MM, Montalto G, Rysz J, Mikhailidis DP, Isenović ER. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. in Current Pharmaceutical Design. 2013;19(21):3869-3877. doi:10.2174/13816128113199990303 .
Banach, Maciej, Rizzo, Manfredi, Obradović, Milan M., Montalto, Giuseppe, Rysz, Jacek, Mikhailidis, Dimitri P., Isenović, Esma R., "PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?" in Current Pharmaceutical Design, 19, no. 21 (2013):3869-3877, https://doi.org/10.2174/13816128113199990303 . .